Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | TK1 | P04183 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DUT | P33316 | 2/20 | 0.34 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TK2 | O00142 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22128493 | 0.81 | KIF11 (0.50) | KIF11TK1NPC1TSHRHRH4 | |
| SCHEMBL9371526 | 0.79 | KIF11 (0.57) | KIF11TK1TSHRHRH4DUT | |
| SCHEMBL705090 | 0.78 | KIF11 (0.50) | KIF11TK1TSHRHRH4DUT | |
| SCHEMBL5325668 | 0.78 | KIF11 (0.55) | KIF11TK1TSHRHRH4DUT | |
| SCHEMBL10434694 | 0.76 | NPC1 (0.46) | NPC1TSHRMAPTATMKCNN4 | |
| SCHEMBL8847011 | 0.76 | MAPK1 (0.38) | KIF11NPC1TSHRMAPTMAOB | |
| SCHEMBL5323607 | 0.76 | KIF11 (0.53) | KIF11TK1TSHRHRH4DUT | |
| SCHEMBL9371537 | 0.75 | KIF11 (0.47) | KIF11TK1HRH4DUTMAPK1 | |
| SCHEMBL5326522 | 0.75 | KIF11 (0.52) | KIF11TK1TSHRHRH4DUT | |
| SCHEMBL11275984 | 0.74 | KIF11 (0.74) | KIF11TK1TSHRHRH4DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0827423-B1 | FUNCTIONALIZED CHAIN EXTENDED INITIATORS FOR ANIONIC POLYMERIZATION | FMC CORP (US) | 2007-12-12 | — | — | EP | claimed |
| US-20240417420-A1 | POLAR CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| WO-2023060021-A1 | POLAR CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | MAGNANI JOHN L (US) | 2023-04-13 | — | — | WO | disclosed |
| US-9708279-B2 | 2-acylaminothiazoles for the treatment of cancer | UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) | 2017-07-18 | — | — | US | disclosed |
| US-9708279-B2 | 2-acylaminothiazoles for the treatment of cancer | UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) | 2017-07-18 | — | — | US | disclosed |
| US-9708279-B2 | 2-acylaminothiazoles for the treatment of cancer | UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) | 2017-07-18 | — | — | US | disclosed |
| EP-3016948-B1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2017-05-10 | — | — | EP | disclosed |
| EP-3016948-B1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2017-05-10 | — | — | EP | disclosed |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) | 2016-09-08 | — | — | US | disclosed |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) | 2016-09-08 | — | — | US | disclosed |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) | 2016-09-08 | — | — | US | disclosed |
| EP-3016948-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | Università Degli Studi Di Milano - Bicocca (IT) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015001024-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015001024-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417420-A1 | POLAR CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | SIGLEC9, SIGLEC7, ASGR1 | KIF11 4153/4885TK1 483/4885NPC1 986/4885 |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | ALK, ERBB2, ABL1 | KIF11 2209/4885TK1 155/4885NPC1 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.